Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution.

By M. Dobrovolskaia, Parag Aggarwal, Jennifer B Hall, S. McNeil. Molecular Pharmaceutics, 2008

982 citations recorded by the source corpus.

Subfields: Biomaterials, Molecular Biology, Polymers and Plastics

View Paper: https://www.semanticscholar.org/paper/aed18755f9bea95dbbc3cd84e9ee04c683ec7157

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Molecular Biology

In Polymers and Plastics

Citations in the corpus

Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging (2009, background): “NP pharmacokinetics and cellular uptake in vivo, including their ability to manage biological barriers, are largely related to NP physicochemical properties, including morphology, hydrodynamic size, charge, and other surface properties [40,41].”
Challenges in Development of Nanoparticle-Based Therapeutics (2012, background): “A list of in vitro assays can test the interaction of nanoparticles with the immune system, which include assays for hemolysis, platelet aggregation, plasma coagulation, complement activation, plasma protein binding, phagocytosis, CFU-GM, leukocyte proliferation, nitric oxide production by macrophag”
Nanoparticles for Cancer Therapy: Current Progress and Challenges (2021, methodology): “To overcomes this, we can use certain methods that can test numerous nano-formulation and by selective iterations selecting a single optimized formulation [190-192].”
Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? (2010, positive): “For example, injecting gold nanoparticles in the blood could cause either blood clotting or hemolysis (blood cells break open and release their hemoglobin) ( Dobrovolskaia et al. 2008 ).”
RNA interference in the clinic: challenges and future directions (2010, background): “Nanoparticle uptake by immune cells in circulation, such as monocytes, leukocytes, platelets and dendritic cells, occurs through various pathways and is facilitated by the adsorption of opsonins to the surface of the particl”
Biocompatibility of engineered nanoparticles for drug delivery. (2013, background): “metal colloids, ceramics) [13,21,52,112], for they do not require future removal [113].”
The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles (2011, positive): “For the drug delivery application in cancer therapy, the nonspecific uptake of NPs by macrophages in the RES may be minimized through manipulation of particle size and surface charge [19,22].”
The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. (2011, background): “particle-based drugs may have improved solubility and altered pharmacokinetics and biodistributions compared to small molecule drugs.(1) 3 The future success of nanoparticle-based nanomedicine requires na-”